Phase Ii clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma
Cohen, M.H.; Broder, L.E.; Fossieck, B.E.; Ihde, D.C.; Minna, J.D.
Cancer Treatment Reports 61(3): 489-490
1977
ISSN/ISBN: 0361-5960 PMID: 194694 Document Number: 112631
VP-16-213 [4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)] is active in small cell bronchogenic carcinoma. There appears to be no cross resistance between this drug and other commonly used agents in this disease. The response rate of 25% seen in this study, in a patient population with advanced disease, is comparable to the response rates for other active single agents including cyclophosphamide, adriamycin, vincristine, methotrexate, procarbazine and the nitrosoureas. The very predictable and generally mild toxicity of this drug makes it a potentially ideal agent to use in combination regimens in small cell bronchogenic carcinoma.